Navigation Links
Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its,Ghrelin Antagonist Program at the American Diabetes Association's,Annual Meeting

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun 25, 2007 - Elixir Pharmaceuticals, Inc., today announced the presentation of two sets of preclinical data demonstrating that ghrelin antagonism may be a potential method for future treatment of a range of metabolic disorders. These data demonstrated a variety of beneficial metabolic effects, notably decreasing body weight, improvements in blood glucose and insulin levels, and reductions in fatty liver. The data were presented in poster sessions on Sunday, June 24th, during the American Diabetes Association's 67th Annual Scientific Sessions meeting, being held in Chicago, IL. Elixir is focused on the development of drugs to treat and prevent metabolic disease, as well as prevent age-related diseases, based on targets identified in the pathways regulating aging.

Ghrelin, which has been identified as a key metabolic regulator, is known to stimulate appetite and food consumption and is believed to play a key role in metabolism and energy storage. A naturally occurring hormone produced in the stomach, ghrelin is believed to act primarily at the level of the hypothalamus in the brain, which governs metabolism.

Elixir scientists have previously demonstrated that, compared to normal (control) mice, ghrelin receptor (GhrR) knockout mice resist the development of diabetes and obesity associated with a high-fat diet. After fifteen weeks of eating a high fat diet the normal (control) mice gained 10% more weight than GhrR knockout mice. Importantly, the knockout mice also had significantly lower blood glucose, insulin and HbA1c levels. These results illustrate the knockout mice resist the development of type 2 diabetes.

In the first poster Elixir presents data in which scientists compared the results of the GhrR knockout mice to those obtained with mice treated twice a day for up to 56 days with one of Elixir's potent, small molecule, oral GhrR antagonists. As with the Gh rR knockout mice, the antagonist-treated mice on a high-fat diet showed decreased body weight, as well as improved glucose and insulin control compared to the mice treated with vehicle. In addition, GhrR antagonist treatment resulted in a significant reduction in liver fat content and improved liver function (as measured by liver enzyme levels) relative to the vehicle-treated mice. The results demonstrate that GhrR antagonist treatment of normal high fat-fed mice completely recapitulates the phenotype of the high fat fed GhR knockout mice.

A second poster presentation explored whether ghrelin exerts a direct effect on adipocytes (fat cells) and if the effect is mediated through ghrelin receptor mRNA expression in these cells. To assess this, the scientists first examined ghrelin signaling by measuring insulin sensitivity in mouse adipocyte cell lines that were treated with ghrelin for four days. Scientists also assessed the expression of GhrR mRNA in adipose tissue, isolated adipocytes from mice, and the mouse adipocyte cell-line. The results showed GhrR was detected in the isolated adipocytes and mouse adipocyte cell lines, suggesting ghrelin acts directly through its receptor on adipocytes to regulate energy homeostasis. Moreover, the reduction of insulin signaling in adipocytes by chronic ghrelin treatment provides a possible mechanism for increased insulin sensitivity in GhrR knockout mice.

"Ghrelin antagonism represents one of the most fascinating and promising therapeutic approaches in diabetes and obesity research today because of its integral role in regulating metabolism. These preclinical data validate our hypothesis that by inhibiting ghrelin's normal function with a potent, small molecule therapeutic, one can effectively improve glucose control, manage body weight, and regulate metabolism. Should this approach be confirmed in clinical testing, we believe ghrelin inhibition could represent a significant advance for the treatment of serious a nd debilitating metabolic disorders such as Type 2 diabetes and obesity," stated Peter DiStefano, Ph.D., Chief Scientific Officer. "We are rapidly advancing our EX-1350 ghrelin antagonist and plan to initiate Phase I testing early next year."

According to the International Diabetes Federation, Type 2 diabetes affects 195 million people worldwide, and the number of sufferers could top 330 million by 2025.

Elixir has filed broad intellectual property protection on all aspects of the ghrelin antagonist program including composition of matter protection covering five novel compound classes and their therapeutic uses.

About Elixir Pharmaceuticals

Elixir is a Cambridge, MA-based biopharmaceutical company focused on developing and commercializing drugs to treat and prevent metabolic disease, prevent age-related diseases, ultimately extending the quality and length of human life.

In addition to its ghrelin antagonist program, the Company has leveraged its knowledge of ghrelin biology and pharmacology by licensing a small molecule ghrelin agonist (designated EX-1314) from Bristol-Myers Squibb Company in April 2005. EX-1314 binds selectively to the ghrelin receptor and mimics the body's naturally occurring ghrelin. In doing so this novel, orally available agent is capable of stimulating appetite, gastric motility and the release of growth hormone. Elixir is currently in IND-enabling studies with EX-1314 targeting a variety of therapeutic indications.

Further, in March 2006, Elixir in-licensed North and South American rights to Glufast(R) (mitiglinide calcium hydrate), an insulin secretagogue, which lowers post-meal glucose levels by improving the body's own ability to produce insulin. Already marketed in Japan, Glufast has undergone extensive clinical development demonstrating the product's ability to safely and effectively treat Type 2 diabetes.

Elixir has also developed expertise and a broad IP portfolio of more than twenty p atents and patent applications related to the Sirtuin class of proteins, including small molecular weight SIRT1 activators and inhibitors. The Company's own R&D efforts and those of its numerous research partners utilizing modulators of SIRT1 (a human sirtuin) have significantly extended the SIRT knowledge base in recent years. Elixir is also actively pursuing drug discovery efforts focused on other key targets, such as AMP-activated kinase (AMPK), which Elixir has shown to be implicated in the regulation of aging and metabolism in a variety of organisms.

More information about Elixir is available at http://www.elixirpharm.com/

Contact

Elixir Pharmaceuticals
William Heiden, 617-995-7000
or
Media:
Burns McClellan for Elixir Pharmaceuticals
Justin Jackson
jjackson@burnsmc.com
or
Jason Farber
jfarber@burnsmc.com
or
Investors:
Juliane Snowden
jsnowden@burnsmc.com
or
Nicki Kahner
nkahner@burnsmc.com
212-213-0006


'"/>




Related medicine technology :

1. Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes
2. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 24, 2016 Een app die ... zij collectief patiënten kunnen behandelen, hun kennis kunnen delen ... achter de nieuwe en revolutionaire MDLinking App, ontwikkeld door ... vaatchirurg dr. Hans Flu en oncologisch chirurg dr. ... beschikbaar is, wordt op dinsdag 24 mei officieel gepresenteerd ...
(Date:5/23/2016)... 23, 2016 Transparency Market Research ... Pancreatic Insufficiency Market - Global Industry Analysis, Size, Share, ... to the report, the exocrine pancreatic insufficiency market is ... 2015 to 2023 to reach US$2.85 Bn by 2023. ... characterized by the deficiency of the exocrine pancreatic enzymes, ...
(Date:5/23/2016)... 2016 Non-invasive diagnostic test realizes ... diseases; ,Technology to be presented at Yissum’s booth, at ... Development Company of the Hebrew University of Jerusalem ... with Aurum Ventures MKI, the technology investment arm of ... diagnostic approach for early detection of multiple diseases by ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 -- Grow ... its Advisory Board. Joining the Grow Healthy Advisory Board team ... them embody the mission of our organization and bring talent, expertise ... them as we continue to expand our footprint as the leader ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... A newly ... rely heavily on their access to trusted resources, both in face-to-face interactions and online. ... Men of Color,” researchers concluded that the creative use of mobile digital devices can ...
(Date:5/24/2016)... DC (PRWEB) , ... May 24, 2016 , ... ... consumers for 2016 increased by 9.3 million people, or 10% over last year, ... number of people covered under group policies was comparatively stable, with a slight ...
(Date:5/24/2016)... ... 2016 , ... Controlling and maintaining the home’s water heater just got infinitely ... Water Heater Controller , a first-of-its-kind system that enables remote and convenient control of ... thermostat does for HVAC systems, Aquanta gives users a much more efficient, versatile way ...
(Date:5/24/2016)... ... ... The Dream Builders Project, a 501(c)3 nonprofit organization based in Los Angeles, ... Mexico on Saturday, May 21st. The volunteers took the children out for the day ... 15 volunteers traveled from Los Angeles to Tijuana, Mexico for the day in the ...
Breaking Medicine News(10 mins):